To determine whether an intervention with smoking cessation starting 4 weeks before general and orthopedic surgery would reduce the frequency of postoperative complications.
Complications are a major concern after elective surgery and smokers have an increased risk. There is insufficient evidence concerning how the duration of preoperative smoking intervention affects postoperative complications.
A randomized controlled trial, conducted between February 2004 and December 2006 at 4 university-affiliated hospitals in the Stockholm region, Sweden. The outcome assessment was blinded. The follow-up period for the primary outcome was 30 days. Eligibility criteria were active daily smokers, aged 18 to 79 years. Of the 238 patients assessed, 76 refused participating, and 117 men and women undergoing surgery for primary hernia repair, laparoscopic cholecystectomy, or a hip or knee prosthesis were enrolled.
Smoking cessation therapy with individual counseling and nicotine substitution started 4 weeks before surgery and continued 4 weeks postoperatively. The control group received standard care. The main outcome measure was frequency of any postoperative complication.
An intention-to-treat analysis showed that the overall complication rate in the control group was 41%, and in the intervention group, it was 21% (P = 0.03). Relative risk reduction for the primary outcome of any postoperative complication was 49% and number needed to treat was 5 (95% CI, 3–40). An analysis per protocol showed that abstainers had fewer complications (15%) than those who continued to smoke or only reduced smoking (35%), although this difference was not statistically significant.
Perioperative smoking cessation seems to be an effective tool to reduce postoperative complications even if it is introduced as late as 4 weeks before surgery.
Smoking cessation therapy starting 4 weeks before surgery was compared to usual care. Primary outcome was frequency of any postoperative complications within 30 days. An intention-to-treat analysis showed that the complication rate in the control group was 41%, and in the intervention group, it was 21% (P = 0.03).
From the *Surgery Section, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute; †Department of Medicine, Clinical Epidemiology Unit, Karolinska University Hospital Solna, Stockholm, Sweden; ‡Clinical Unit of Health Promotion/WHO Collaborating Center for Evidence-Based Health Promotion, Bispebjerg University Hospital, Copenhagen, Denmark; and §Orthopedics Section, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute, Stockholm, Sweden.
Supported by the The Swedish National Institute of Public Health and the Regional County Council (Stockholms Läns Landsting). Pfizer financed the nicotine replacement therapy.
None of the funders took part in the design and conduct of the study; in collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Trial Registration: clinicaltrials.gov. Identifier: NCT00533000.
Reprints: David Lindström, MD, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute, 118 83 Stockholm, Sweden. E-mail: David.email@example.com.